- Dec 15, 2016
NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Phase I Trial of Universal Donor NK Cell Therapy...
45
- Dec 9, 2016
NCT02655458: Phase 1 - Elotuzumab in Comb. With Auto transplant and Lenalidomide Maintenance in MM
The purpose of this study is to explore the combination of Elotuzumab in combination with autologous stem cell transplantation and...
233
- Dec 9, 2016
NCT02658929: Phase 1 - Study of bb2121 in BCMA-Expressing refractory Multiple Myeloma CRB-401
CRB-401 NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma Study CRB-401...
436
- Dec 9, 2016
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM A Study of PVX-410, a Cancer...
184
- Dec 8, 2016
NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
AMG 176 NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML AMG 176 First in Human Trial in...
212
- Dec 1, 2016
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma Establish the MTD of Lintuzumab-Ac225 as monotherapy...
63